论文部分内容阅读
乳腺癌中HER2 /neu基因扩增与预后不良密切相关。抗HER2 /neu癌蛋白的单抗荷塞停治疗乳腺癌已取得显著效果 ,但仅HER2 /neu过度表达的患者能受益于荷塞停治疗 ,因此治疗开始前确定患者癌组织HER2 /neu表达水平对治疗成功至关重要。
Breast cancer HER2 / neu gene amplification and poor prognosis are closely related. HER2 / neu oncoprotein monoclonal antibody celecoxib has achieved significant results in breast cancer, but only HER2 / neu overexpression patients can benefit from the cefazed treatment, so before the start of treatment to determine the level of HER2 / neu expression in cancer tissue Critical to the success of the treatment.